Compare Ascendis Pharma A/S (ASND) vs Redwire Corporation (RDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Redwire Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Redwire Corporation trades at $10.04 (market cap $2.43B). The key difference: Ascendis Pharma A/S is far larger — about 7.3× Redwire Corporation's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| ASND | RDW | |
|---|---|---|
Market Cap | $17.74B | $2.43B |
Sector | Health | Technology |
52-Week High | $277.18 | $25.90 |
52-Week Low | $163.32 | $5.06 |
Enterprise Value | $18.11B | $2.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
RDW trades at $10.18, down 2.77% today amid bearish technical signals despite bullish analyst sentiment. The stock shows weak fundamentals with a -80.9% net income margin and three consecutive quarterly EPS misses. Recent news highlights volatility driven by SpaceX's market impact and RDW's capital raising activities, though new defense contracts provide some optimism.
The outlook remains high-risk due to persistent losses and cash burn, but analyst consensus suggests 87% upside to the $19 price target. Key risks include dilution from fundraising and intense space sector competition, requiring careful monitoring of profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
